8-K: Pacira BioSciences Royalty Dispute Takes Negative Turn

Pacira BioSciences faces a setback in its royalty dispute with RDF as an appeals court partially reverses a prior judgment, reinstating royalty obligations for certain EXPAREL manufacturing processes.

Summary

• Pacira BioSciences, Inc. (Pacira) has received an unfavorable ruling from the United States Court of Appeals for the Ninth Circuit regarding a royalty dispute with the Research Development Foundation (RDF).
• The appeals court reversed a prior district court judgment in part, determining that Pacira owes royalties on EXPAREL manufactured using its 200-liter process.
• This decision directs the district court to enter judgment in favor of RDF on this specific claim.
• The appeals court also remanded the case to recalculate pre-judgment interest owed by RDF to Pacira on the 45-liter EXPAREL portion of the original judgment.
• Pacira had previously been granted summary judgment and a favorable trial verdict, leading to the elimination of royalty payments and a $23.1 million repayment sought from RDF, plus interest.
• The company received $28.3 million in July 2025, encompassing the repaid royalties and statutory interest, after a district court ruling in June 2025.
• Pacira is currently evaluating its legal options and intends to defend its rights vigorously, but cannot predict the outcome.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the unfavorable appeals court ruling, which reverses a prior favorable judgment and reintroduces royalty obligations.

Positives

• The Court of Appeals remanded the matter to recalculate pre-judgment interest RDF owes to Pacira on the 45-liter EXPAREL portion of the judgment, potentially still resulting in a financial benefit to Pacira for that specific aspect.
• Pacira previously received a $28.3 million cash payment in July 2025, which included repaid royalties and interest, stemming from the district court's favorable ruling on the 45-liter batch manufacturing process.

Negatives

• The United States Court of Appeals for the Ninth Circuit reversed the District Court's judgment in part, ruling that Pacira owes royalties on EXPAREL manufactured using its 200-liter process.
• This decision reinstates royalty obligations for a portion of EXPAREL sales, contrary to the prior favorable district court ruling.
• The company is now obligated to pay royalties on EXPAREL produced via the 200-liter manufacturing process.
• Pacira is unable to predict the outcome of further legal actions and is evaluating its options.

Risks

• The company faces ongoing legal uncertainty and potential financial obligations related to royalty payments for EXPAREL manufactured under the 200-liter process.
• The outcome of the remanded proceedings to recalculate pre-judgment interest for the 45-liter EXPAREL portion remains uncertain.
• Pacira's ability to vigorously defend its rights and the ultimate resolution of the dispute are subject to legal processes and outcomes.

Future Outlook

The company is evaluating its legal options and intends to vigorously defend its rights, but the outcome of the ongoing legal action remains unpredictable at this time.

Management Comments

• The Company is evaluating its legal options and intends to vigorously defend its rights in this action.
• The Company is unable to predict the outcome of this action at this time.

Industry Context

StockSavvy.ai notes that this development highlights the inherent risks in patent disputes and royalty agreements within the pharmaceutical and biotechnology sectors, where intellectual property protection and licensing are critical to revenue streams. The protracted legal battle over EXPAREL royalties underscores the significant financial implications of patent validity and interpretation.

Legal Proceedings

• Declaratory judgment lawsuit filed by Pacira in the U.S. District Court for the District of Nevada (21-cv-02241) seeking a declaration that no royalties are owed to RDF after December 24, 2021.
• U.S. District Court granted Pacira partial summary judgment regarding royalties for EXPAREL made under its 45-liter batch manufacturing process.
• Trial conducted in September 2024 regarding royalties on EXPAREL made under the enhanced, larger-scale manufacturing process.
• District Court issued judgment in favor of Pacira in April 2025 regarding the enhanced manufacturing process.
• District Court issued judgment in June 2025 ordering RDF to repay $23.1 million in royalties and $5.2 million in statutory interest.
• RDF filed two notices of appeal in May and September 2025.
• United States Court of Appeals for the Ninth Circuit reversed the District Court's judgment in part on November 6, 2026, holding Pacira owes royalties on EXPAREL manufactured using its 200-liter process and remanded the matter for recalculation of pre-judgment interest on the 45-liter portion.

Related Party Transactions

• Agreement between Research Development Foundation (RDF) and a wholly-owned subsidiary of Pacira BioSciences, Inc. requiring Pacira to pay a low single-digit royalty on revenues from certain products as long as certain patents remain valid.

Stakeholder Impact

• Shareholders: Potential negative impact due to the unfavorable appeals court ruling, which could lead to future royalty payments and increased legal costs.
• Creditors: No immediate direct impact, but long-term financial health could be affected by ongoing litigation expenses and potential future royalty obligations.
• RDF: The appeals court ruling is favorable to RDF, reinstating royalty claims for a portion of EXPAREL sales.

Next Steps

• Pacira will evaluate its legal options.
• Pacira intends to vigorously defend its rights.
• The District Court will recalculate pre-judgment interest RDF owes to Pacira on the 45-liter EXPAREL portion of the judgment.

Key Dates

Recommendation

The unfavorable appeals court ruling introduces significant uncertainty and potential financial liability regarding royalty payments for EXPAREL. While the company is evaluating its options, the reversal of a prior favorable judgment suggests a more challenging legal path ahead. The potential for ongoing litigation costs and future royalty obligations warrants a cautious 'hold' stance until the outcome is clearer and the financial impact can be better assessed.

Keywords

royalty dispute, EXPAREL, patent litigation, declaratory judgment, appeals court, manufacturing process, intellectual property